Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma
Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma
复制标题
Interleukin-11 受体可预测早期透明细胞肾细胞癌患者的术后临床结果。
DOI：
10.1093/jjco/hyu194
复制
发表时间：
2015-02-01
影响因子：
2.4
通讯作者：
Gu, Jianxin
中科院分区：
文献类型：
--
作者：
Pan, Deng;Xu, Le;Gu, Jianxin
目的：探讨白细胞介素11受体A链在早期肾透明细胞癌中的预后价值。白细胞介素-11受体A链，一个成员的gp 130依赖性受体，发挥多效致癌活性，促进增殖，血管生成和转移在许多cancer.Methods：我们回顾性招募了293例（130在培训队列和163在验证队列）与早期（TNM分期I + II）透明细胞肾细胞癌在一个单一的机构进行肾切除术。记录临床病理特征、无复发生存期和总生存期。通过免疫组织化学评估肿瘤组织中的白细胞介素-11受体a链强度。Kaplan-Meier法比较各组生存曲线。采用考克斯回归模型分析预后因素对无复发生存期和总生存期的影响。计算一致性指数以评估预测准确性。结果：在训练和验证队列中，白细胞介素11受体α链的高表达与早期肾透明细胞癌患者的早期复发（分别为P = 0.004和P = 0.015）和生存不良（分别为P < 0.001和P = 0.019）相关。多变量分析证实，白细胞介素-11受体α链表达是无复发生存期（P = 0.004）和总生存期（P = 0.001）的独立预后因素。Leibovich预后评分的预测准确性提高时，白细胞介素-11受体α链的表达纳入。值得注意的是，改善的预测主要发生在低风险疾病定义的Leibovich score.Conclusion：高白细胞介素-11受体α链表达是一个独立的预测不良的临床结果在早期肾透明细胞癌患者，预后价值是在低风险疾病更突出。
Objective: To investigate the prognostic value of interleukin-11 receptor a chain in patients with early-stage clear-cell renal cell carcinoma. Interleukin-11 receptor a chain, a member of the gp130-dependent receptors, exerts pleiotropic oncogenic activities by promoting proliferation, angiogenesis and metastasis in many cancers.Methods: We retrospectively enrolled 293 patients (130 in the training cohort and 163 in the validation cohort) with early-stage (TNM Stage I + II) clear-cell renal cell carcinoma undergoing nephrectomy at a single institution. Clinicopathologic features, recurrence-free survival and overall survival were recorded. Interleukin-11 receptor a chain intensities were assessed by immunohistochemistry in tumor tissues. Kaplan-Meier method was applied to compare survival curves between groups. Cox regression models were used to analyze the impact of prognostic factors on recurrence-free survival and overall survival. The concordance index was calculated to assess predictive accuracy.Results: In both training and validation cohorts, high interleukin-11 receptor a chain expression was associated with early recurrence (P = 0.004 and P = 0.015, respectively) and poor survival (P < 0.001 and P = 0.019, respectively) of patients with early-stage clear-cell renal cell carcinoma. Multivariate analyses confirmed that interleukin-11 receptor a chain expression was an independent prognostic factor for recurrence-free survival (P = 0.004) and overall survival (P = 0.001). The predictive accuracy of the Leibovich prognostic score was improved when interleukin-11 receptor a chain expression was incorporated. Notably, the improvement in prediction mainly took place in patients with low-risk disease defined by the Leibovich score.Conclusion: High Interleukin-11 receptor a chain expression is an independent predictor of poor clinical outcome in patients with early-stage clear-cell renal cell carcinoma, and the prognostic value is more prominent in those with low-risk disease.